These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25115545)

  • 1. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease.
    Gong B; Levine S; Barnum SR; Pasinetti GM
    Curr Alzheimer Res; 2014; 11(7):637-44. PubMed ID: 25115545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.
    Gong B; Pan Y; Zhao W; Knable L; Vempati P; Begum S; Ho L; Wang J; Yemul S; Barnum S; Bilski A; Gong BY; Pasinetti GM
    Mol Immunol; 2013 Dec; 56(4):619-29. PubMed ID: 23911420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins for Alzheimer's disease.
    Puli L; Tanila H; Relkin N
    Curr Alzheimer Res; 2014; 11(7):626-36. PubMed ID: 25115546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.
    Wang T; Xie XX; Ji M; Wang SW; Zha J; Zhou WW; Yu XL; Wei C; Ma S; Xi ZY; Pang GL; Liu RT
    Neuropharmacology; 2016 Jun; 105():561-576. PubMed ID: 26907803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
    Kasai T; Kondo M; Ishii R; Tanaka A; Ataka S; Shimada H; Tomiyama T; Mori H; Taylor M; Allsop D; Nakagawa M; Mizuno T; Tokuda T
    PLoS One; 2017; 12(4):e0174630. PubMed ID: 28394917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.
    Dodel R; Neff F; Noelker C; Pul R; Du Y; Bacher M; Oertel W
    Drugs; 2010 Mar; 70(5):513-28. PubMed ID: 20329802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
    Hettinger JC; Lee H; Bu G; Holtzman DM; Cirrito JR
    Mol Neurodegener; 2018 May; 13(1):22. PubMed ID: 29764453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials of intravenous immunoglobulin for Alzheimer's disease.
    Relkin N
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S74-9. PubMed ID: 24760112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
    Solomon B
    Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration.
    Loeffler DA; Klaver AC; Coffey MP
    Autoimmunity; 2015 Jun; 48(4):196-200. PubMed ID: 25392130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?
    Loeffler DA
    J Neuroinflammation; 2014 Dec; 11():198. PubMed ID: 25476011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin therapy for autoimmune diseases.
    Arnson Y; Shoenfeld Y; Amital H
    Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
    Klaver AC; Coffey MP; Smith LM; Loeffler DA
    Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
    Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
    Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.
    Counts SE; Ray B; Mufson EJ; Perez SE; He B; Lahiri DK
    J Clin Immunol; 2014 Jul; 34 Suppl 1(0 1):S80-5. PubMed ID: 24760109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
    Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations.
    Klaver AC; Finke JM; Digambaranath J; Balasubramaniam M; Loeffler DA
    Int Immunopharmacol; 2010 Jan; 10(1):115-9. PubMed ID: 19840873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults.
    Lahiri DK; Ray B
    Curr Alzheimer Res; 2014; 11(7):645-54. PubMed ID: 25115544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E; Platt JL; Frank MM
    J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.